Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs Kenvue Inc. Common Stock (KVUE) Price & Performance

Ginkgo Bioworks Holdings IncTrade
Kenvue Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs Kenvue Inc. Common Stock — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13.2 (market cap $763.64M), while Kenvue Inc. Common Stock trades at $17.71 (market cap $34.06B). The key difference: Kenvue Inc. Common Stock is far larger — about 44.6× Ginkgo Bioworks Holdings Inc's market cap, and Kenvue Inc. Common Stock pays a 4.74% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.

DNAKVUE
Market Cap
$763.64M$34.06B
Volume
3,204,17723,267,228
Sector
HealthConsumer Staples
52-Week High
$15.83$19.83
52-Week Low
$5.48$14.11
Typical Hold Time
7 Days—
Enterprise Value
$865.59M$41.56B
Dividend Yield
—4.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

Kenvue Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DNA
53% Buy47% Sell
Avg holding period · 7 Days
KVUE

No sentiment data available yet.

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA →

About Kenvue Inc. Common Stock

Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.

Read more on KVUE →